Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation (2016)

Historic Accumulated Depreciation for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q4 2016 value amounting to $13.4 million.

  • Agios Pharmaceuticals' Accumulated Depreciation rose 7447.81% to $13.4 million in Q4 2016 from the same period last year, while for Dec 2016 it was $13.4 million, marking a year-over-year increase of 7447.81%. This contributed to the annual value of $13.4 million for FY2016, which is 7447.81% up from last year.
  • As of Q4 2016, Agios Pharmaceuticals' Accumulated Depreciation stood at $13.4 million, which was up 7447.81% from $7.7 million recorded in Q4 2015.
  • In the past 5 years, Agios Pharmaceuticals' Accumulated Depreciation ranged from a high of $13.4 million in Q4 2016 and a low of $2.8 million during Q4 2012
  • Over the past 5 years, Agios Pharmaceuticals' median Accumulated Depreciation value was $5.6 million (recorded in 2014), while the average stood at $6.7 million.
  • In the last 5 years, Agios Pharmaceuticals' Accumulated Depreciation surged by 3261.75% in 2014 and then soared by 7447.81% in 2016.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Accumulated Depreciation stood at $2.8 million in 2012, then surged by 52.34% to $4.2 million in 2013, then soared by 32.62% to $5.6 million in 2014, then skyrocketed by 37.89% to $7.7 million in 2015, then skyrocketed by 74.48% to $13.4 million in 2016.
  • Its last three reported values are $13.4 million in Q4 2016, $7.7 million for Q4 2015, and $5.6 million during Q4 2014.